← All trials
NCT02010957
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2015
- Primary completion
- May 31, 2019
- Completion date
- Jun 30, 2020
- First posted
- Dec 13, 2013
- Last posted
- Apr 11, 2018
- Enrollment
- 220
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Julius-Maximilians UniversityLead sponsor
- Assistance Publique - Hôpitaux de ParisCollaborator
- University of CambridgeCollaborator
- Humboldt UniversityCollaborator
- Gottfried Wilhelm Leibniz Universität HannoverCollaborator
- University of DuesseldorfCollaborator
- Johannes Gutenburg UniversityCollaborator
- Ludwig Maximilians UniversityCollaborator
- University of Duisburg-EssenCollaborator
- Radboud UniversityCollaborator
- University of FlorenceCollaborator
- University of LeipzigCollaborator
- University of PadovaCollaborator
- University of ViennaCollaborator
- Julius-Maximilians UniversityOverall official - principal investigator
- Uppsala UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.